ライフサイエンスコーパス: Lp-PLA2

1 ty-five percent of participants had abnormal Lp-PLA2.

2 tory response in part by effects elicited by Lp-PLA2.

3 mans is characterized by local production of Lp-PLA2.

4 for apoB, only prava40 led to a reduction in Lp-PLA2 (-15%, p = 0.008) and atorva10 to a decrease in

5 lesterol, 19.8% for interleukin-6, 26.2% for Lp-PLA2, 38.5% for high-sensitivity C-reactive protein,

6 risk of coronary heart disease (CHD), making Lp-PLA2 a potential therapeutic target.

7 Lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of the phospholipase A2 family of enz

8 therapy significantly decreased the level of Lp-PLA2, a vascular-specific, inflammatory enzyme that p

9 ) PLA2G7 single-nucleotide polymorphisms and Lp-PLA2 activity (3 prospective, 2 case-control, 2 cross

10 mg/d was associated with a 20% reduction in Lp-PLA2 activity (P<0.001), whereas Lp-PLA2 rose 3.6% wi

11 V events was similar across all quintiles of Lp-PLA2 activity (Ptrend=0.88).

12 T and PI use were positively associated with Lp-PLA2 activity and mass after adjusting for age, race,

13 Lp-PLA2 activity correlated with several CHD risk marker

14 PLA2G7 variants associated with Lp-PLA2 activity could evaluate whether this relationshi

15 y lipoprotein (LDL), and C-reactive protein, Lp-PLA2 activity in the highest quintile remained indepe

16 Patients with 30-day Lp-PLA2 activity in the highest quintile were at signifi

17 At 30 days, Lp-PLA2 activity is significantly lowered with high-dose

18 Adding Lp-PLA2 activity tertiles to the model improved the pred

19 xamine the association of the following: (1) Lp-PLA2 activity versus cardiovascular biomarkers and ri

20 events for the top versus bottom quartile of Lp-PLA2 activity were 1.61 (95% confidence interval, 1.3

21 Plasma levels of Lp-PLA2 activity were measured at baseline (n=3648) and

22 7 variants associated with modest effects on Lp-PLA2 activity were not associated with cardiovascular

23 Unlike Lp-PLA2 activity, PLA2G7 variants associated with modest

24 t of lysophosphatidylcholine, the product of Lp-PLA2 activity, was documented on the mineralization o

25 A379V) showed the strongest association with Lp-PLA2 activity, with VV subjects having 7.2% higher ac

26 eaction, immunohistochemistry, and enzymatic Lp-PLA2 activity.

27 Risk Score tertile had significantly higher Lp-PLA2 activity.

28 er lipoprotein-associated phospholipase A(2)(Lp-PLA2) activity is associated with increased risk of c

29 ted lipoprotein-associated phospholipase A2 (Lp-PLA2), also called platelet-activating factor acetylh

30 Lp-PLA2, also known as platelet-activating factor acetyl

31 Serum levels of Lp-PLA2, an enzyme that hydrolyzes oxidized phospholipid

32 ard ratio of 1.78 for the highest tertile of Lp-PLA2 and 2.53 for the highest category of CRP versus

33 duals with LDL-C <130 mg/dL, those with both Lp-PLA2 and CRP levels in the highest tertile were at th

34 Lp-PLA2 and CRP levels were higher in the 608 cases than

35 Lp-PLA2 and CRP may be complementary in identifying indi

36 Both Lp-PLA2 and CRP were associated with incident CHD after

37 als with LDL-C below the median (130 mg/dL), Lp-PLA2 and CRP were both significantly and independentl

38 ) in human plasma, this review will focus on Lp-PLA2 and human coronary heart disease.

39 er Lp-PLA2 decrease included higher baseline Lp-PLA2 and IL-6 levels, smaller increases in total chol

40 This study has investigated whether Lp-PLA2 and its major enzymatic product, lysophosphatidy

41 The Lp-PLA2 and OxLDL were reduced in statin-treated groups,

42 -PLA2, lysophosphatidylcholine (a product of Lp-PLA2), and C-reactive protein.

43 LDL has been shown to be highly enriched in Lp-PLA2; and in advanced atheroma, Lp-PLA2 levels are hi

44 man lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with cardiovascular disease and

45 tinues to build supporting the usefulness of Lp PLA2 as a predictor of coronary events in the general

46 Lp-PLA2 augments the inflammatory response after MI and

47 We evaluated the association between Lp-PLA2, cardiac allograft vasculopathy (CAV) assessed b

48 adults and to determine associations between Lp-PLA2, cardiometabolic risk factors, and subclinical a

49 Lp-PLA2 correlated positively with LDL-C (r=0.36) and ne

50 urther work is necessary to document whether Lp-PLA2 could be considered as a novel target in CAVD.

51 k in Communities study, the relation between Lp-PLA2, CRP, traditional risk factors, and risk for CHD

52 As a specific inhibitor of Lp-PLA2, darapladib has been shown to be protective agai

53 163 levels; factors associated with a larger Lp-PLA2 decrease included higher baseline Lp-PLA2 and IL

54 ce whose bone marrow-derived leukocytes were Lp-PLA2-deficient (bmLp-PLA2 (-/-)).

55 We hypothesized that Lp-PLA2 (encoded by the PLA2G7 gene) is expressed in CAV

56 Recent reports have linked Lp-PLA2 enrichment not only to the most atherogenic of L

57 ladib is an oral, selective inhibitor of the Lp-PLA2 enzyme.

58 Selective inhibition of Lp-PLA2 has been postulated to reduce necrotic core prog

59 Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherog

60 Lipoprotein-associated phospholipase A2 (Lp-PLA2) hydrolyses oxidized low-density lipoproteins in

61 as conducted to describe the distribution of Lp-PLA2 in a cohort of human immunodeficiency virus (HIV

62 to confirm or refute a contributory role for Lp-PLA2 in CHD.

63 ly have data emerged demonstrating a role of Lp-PLA2 in development of advanced coronary artery disea

64 This study tested the role of Lp-PLA2 in healing after MI.

65 A fragment screen was conducted against Lp-PLA2 in order to identify novel inhibitors.

66 The prognostic value of Lp-PLA2 in patients with acute coronary syndromes (ACS)

67 Higher expression of Lp-PLA2 in stenotic aortic valves was confirmed by quant

68 These results support the role for Lp-PLA2 in the mechanism of regional vascular inflammati

69 of lipoprotein-associated phospholipase A2 (Lp-PLA2) in atherosclerosis, partly because of the lack

70 of lipoprotein-associated phospholipase A2 (Lp-PLA2) in calcific aortic valve disease (CAVD).

71 ot definitive proof, of a potential role for Lp PLA2 inhibition in coronary heart disease prevention.

72 Taken together, this study demonstrates that Lp-PLA2 inhibition can effectively prevent diabetes-medi

73 l studies are warranted to determine whether Lp-PLA2 inhibition improves plaque stability and ultimat

74 Systemic Lp-PLA2 inhibition using SB-435495 at 10 mg/kg (i.p.) ef

75 es on the efficacy of darapladib, a specific Lp PLA2 inhibitor, show beneficial changes in plaque mor

76 er effects, or randomized trials of specific Lp-PLA2 inhibitors are needed to confirm or refute a con

77 or lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors may play a role in reducing progress

78 Elevated Lp PLA2 is also associated with stroke and heart failure

79 Lp PLA2 is gaining acceptance as a useful biomarker of c

80 The crystal structure of Lp PLA2 is now available and offers insight into the lin

81 Several studies have confirmed that Lp-PLA2 is an independent risk factor for cardiovascular

82 hypothesis that local coronary production of Lp-PLA2 is enhanced in patients with early coronary athe

83 Lp-PLA2 is highly abnormal in HIV-infected patients and

84 Together, these results demonstrated that Lp-PLA2 is highly expressed in CAVD, and it plays a role

85 Lp-PLA2 is independently associated with progression of

86 Lp-PLA2 is intimately associated with several aspects of

87 Lp-PLA2 is not useful for risk stratification when measu

88 Lp-PLA2 is well placed, whether on an oxidation suscepti

89 Lipoprotein-associated phospholipase A2 (Lp PLA2) is postulated to occupy a key position in the p

90 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel marker and participant in vascular i

91 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a proinflammatory enzyme associated primaril

92 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a risk factor for coronary artery disease (C

93 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an emerging biomarker of cardiovascular dise

94 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is associated with the risk of cardiovascular (

95 sophosphatidylcholine, the active product of Lp-PLA2, is associated with endothelial dysfunction.

96 High Lp-PLA2 level was associated with increase in plaque vol

97 Lp-PLA2 level>236 ng/mL (higher tertile) identified a su

98 vation independently predicted the change in Lp-PLA2 level.

99 ally significant predictors of a decrease in Lp-PLA2 level.

100 the lipoprotein-associated phospholipase A2 (Lp-PLA2) level was seen in the statin group, compared wi

101 tently support a relationship between plasma Lp-PLA2 levels and susceptibility to coronary heart dise

102 riched in Lp-PLA2; and in advanced atheroma, Lp-PLA2 levels are highly upregulated, colocalizing with

103 Elevated Lp-PLA2 levels associate with increased risk of cardiova

104 Lp-PLA2 levels correlate with an increased risk of recur

105 In response to MI, Lp-PLA2 levels markedly increased in the circulation.

106 The Lp-PLA2 levels positively correlated with age (r = 0.09)

107 Elevated Lp-PLA2 levels predict CHD events in apparently healthy

108 Arterial Lp-PLA2 levels were similar in patients and control subj

109 ed to greater decreases in sCD14, hsCRP, and Lp-PLA2 levels, compared with EFV/FTC/TDF.

110 were noted for changes in sCD14, hsCRP, and Lp-PLA2 levels.

111 sk in HIV-infected individuals by decreasing Lp-PLA2 levels.

112 Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels predict incident coronary heart disease

113 e animal models with a human-like pattern of Lp-PLA2 lipoprotein distribution.

114 6-5.19, P=0.012) compared with patients with Lp-PLA2< or =236 ng/mL.

115 artery and coronary sinus for measurement of Lp-PLA2, lysophosphatidylcholine (a product of Lp-PLA2),

116 PI)-based treatment had significantly higher Lp-PLA2 mass and activity than those who were treatment-

117 tid intima-media thickness (cIMT) had higher Lp-PLA2 mass and activity.

118 m (CAC) scores >100 had significantly higher Lp-PLA2 mass than those with lower or nondetectable calc

119 Mean Lp-PLA2 mass was 313 +/- 105 ng/mL and activity 173 +/-

120 sed lipoprotein-associated phospholipase A2 (Lp-PLA2) mass or activity is associated with an increase

121 Lp-PLA2 may be a useful marker for risk of CAV and a the

122 Thus, Lp-PLA2 may be a useful therapeutic target for patients

123 Indeed, Lp-PLA2 may be an important link between lipid homeostas

124 Lp-PLA2 may be used as an additional and more vascular s

125 Higher levels of Lp-PLA2, MCP-1, and oxLDL were associated with higher pl

126 sma lipoprotein-associated phospholipase A2 (Lp-PLA2), Mercodia oxidized LDL (OxLDL) with antibody 4E

127 In particular, Lp-PLA2 might play an important role in plaque vulnerabi

128 Lp-PLA2 net production in the coronary circulation was h

129 , have been shown to reduce plasma levels of Lp-PLA2, none has been studied in terms of its ability t

130 L-6, hs-CRP, and D-dimer and lower levels of Lp-PLA2 (P < .001 for all).

131 onary heart disease this is not the case for Lp-PLA2 polymorphisms.

132 Selective inhibition of Lp-PLA2 reduces development of necrotic cores and may re

133 ction in Lp-PLA2 activity (P<0.001), whereas Lp-PLA2 rose 3.6% with pravastatin 40 mg/d (P<0.001).

134 The number of Lp-PLA2 transcripts correlated with several indexes of t

135 Lp-PLA2 was assessed in 341 (25% women, 52% white, 74% o

136 l nonmineralized aortic valves revealed that Lp-PLA2 was increased by 4.2-fold in mineralized aortic

137 Lp-PLA2 was measured in plasma aliquots using an enzyme-

138 To test the functional importance of Lp-PLA2, we generated chimeric mice whose bone marrow-de

139 Overall, mean levels of Lp-PLA2 were lower at 30 days of follow-up than at basel

140 and lipoprotein-associated phospholipase A2 (Lp-PLA2) were measured at baseline, at 12 months, at 24

141 on (lipoprotein-associated phospholipase A2 [Lp-PLA2]) were compared.

142 factors including LDL-C, the association of Lp-PLA2 with CHD was attenuated and not statistically si

143 perienced an ACS event, direct inhibition of Lp-PLA2 with darapladib added to optimal medical therapy

144 ere used to examine the association of serum Lp-PLA2 with incident CHD (myocardial infarction, angina

145 he large macrophage-mediated upregulation of Lp-PLA2 within advanced plaques.